JP2012504638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504638A5 JP2012504638A5 JP2011530213A JP2011530213A JP2012504638A5 JP 2012504638 A5 JP2012504638 A5 JP 2012504638A5 JP 2011530213 A JP2011530213 A JP 2011530213A JP 2011530213 A JP2011530213 A JP 2011530213A JP 2012504638 A5 JP2012504638 A5 JP 2012504638A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- antigen
- combination
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 201000010099 disease Diseases 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 19
- 230000000735 allogeneic effect Effects 0.000 claims description 11
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 210000000447 Th1 cell Anatomy 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 239000013592 cell lysate Substances 0.000 claims description 4
- 239000006166 lysate Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000037452 priming Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10169208P | 2008-10-01 | 2008-10-01 | |
| US61/101,692 | 2008-10-01 | ||
| US12/570,442 US9695397B2 (en) | 2008-10-01 | 2009-09-30 | Th1 vaccination priming for active immunotherapy |
| US12/570,442 | 2009-09-30 | ||
| PCT/US2009/059177 WO2010039924A2 (en) | 2008-10-01 | 2009-10-01 | Th1 vaccination priming for active immunotheraphy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014092886A Division JP2014139247A (ja) | 2008-10-01 | 2014-04-28 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504638A JP2012504638A (ja) | 2012-02-23 |
| JP2012504638A5 true JP2012504638A5 (https=) | 2012-11-15 |
| JP6042065B2 JP6042065B2 (ja) | 2016-12-14 |
Family
ID=42074205
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011530213A Active JP6042065B2 (ja) | 2008-10-01 | 2009-10-01 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
| JP2014092886A Withdrawn JP2014139247A (ja) | 2008-10-01 | 2014-04-28 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
| JP2016038729A Withdrawn JP2016104818A (ja) | 2008-10-01 | 2016-03-01 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
| JP2017212788A Active JP6789913B2 (ja) | 2008-10-01 | 2017-11-02 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014092886A Withdrawn JP2014139247A (ja) | 2008-10-01 | 2014-04-28 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
| JP2016038729A Withdrawn JP2016104818A (ja) | 2008-10-01 | 2016-03-01 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
| JP2017212788A Active JP6789913B2 (ja) | 2008-10-01 | 2017-11-02 | 能動免疫療法のためのＴｈ１ワクチン接種プライミング |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9695397B2 (https=) |
| EP (1) | EP2334309B1 (https=) |
| JP (4) | JP6042065B2 (https=) |
| CN (2) | CN104758926B (https=) |
| CA (1) | CA2739255C (https=) |
| DK (1) | DK2334309T3 (https=) |
| ES (1) | ES2635516T3 (https=) |
| HU (1) | HUE034855T2 (https=) |
| IL (1) | IL212102A (https=) |
| PL (1) | PL2334309T3 (https=) |
| PT (1) | PT2334309T (https=) |
| WO (1) | WO2010039924A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12012502233A1 (en) * | 2010-04-13 | 2022-10-05 | Immunovative Therapies Ltd | Methods and compositions for inhibition of treg cells |
| SG10201908048QA (en) | 2014-01-08 | 2019-10-30 | Immunovative Therapies Ltd | Treatment of Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome |
| TWI714529B (zh) * | 2015-05-20 | 2021-01-01 | 以色列商梵提夫免疫療法公司 | 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| TWI905535B (zh) | 2018-04-23 | 2025-11-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US20250319132A1 (en) * | 2024-04-16 | 2025-10-16 | Mirror Biologics, Inc. | Methods and compositions for improving the immune response against viral pathogens |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051237A (en) * | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
| US20080199495A1 (en) * | 1999-04-15 | 2008-08-21 | Monash University | Stimulation of thymus for vaccination development |
| US20020131960A1 (en) * | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001294834A1 (en) * | 2000-09-26 | 2002-04-08 | Beth Israel Deaconess Medical Center | Recombinant bcg vaccines for the prevention and treatment of cancer |
| US20070025958A1 (en) * | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| JP2004536800A (ja) * | 2001-05-09 | 2004-12-09 | アルカベロ アクチェセルスカプ | Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物 |
| US20030134415A1 (en) * | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
| US20040115224A1 (en) * | 2002-12-16 | 2004-06-17 | Tsuneya Ohno | Preparation and administration of hybrid cell vaccines for the prevention of cancer |
| NZ542134A (en) * | 2003-03-04 | 2009-06-26 | Alexion Pharma Inc | Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells |
| US7402431B2 (en) * | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| CA2555714C (en) * | 2004-02-26 | 2013-12-03 | Immunovative Therapies, Ltd. | Methods for preparing t-cells for cell therapy |
| US7181931B2 (en) * | 2005-02-28 | 2007-02-27 | White Dennis M | Method and apparatus for fitting chain jewelry assembly on an individual |
| US7435692B2 (en) * | 2005-10-19 | 2008-10-14 | Tokyo Electron Limited | Gas jet reduction of iso-dense field thickness bias for gapfill process |
-
2009
- 2009-09-30 US US12/570,442 patent/US9695397B2/en active Active
- 2009-10-01 WO PCT/US2009/059177 patent/WO2010039924A2/en not_active Ceased
- 2009-10-01 DK DK09818495.5T patent/DK2334309T3/en active
- 2009-10-01 CN CN201510137976.8A patent/CN104758926B/zh active Active
- 2009-10-01 JP JP2011530213A patent/JP6042065B2/ja active Active
- 2009-10-01 HU HUE09818495A patent/HUE034855T2/en unknown
- 2009-10-01 PL PL09818495T patent/PL2334309T3/pl unknown
- 2009-10-01 PT PT98184955T patent/PT2334309T/pt unknown
- 2009-10-01 ES ES09818495.5T patent/ES2635516T3/es active Active
- 2009-10-01 EP EP09818495.5A patent/EP2334309B1/en active Active
- 2009-10-01 CA CA2739255A patent/CA2739255C/en active Active
- 2009-10-01 CN CN200980147749.6A patent/CN102227224B/zh active Active
-
2011
- 2011-04-03 IL IL212102A patent/IL212102A/en active IP Right Grant
-
2014
- 2014-04-28 JP JP2014092886A patent/JP2014139247A/ja not_active Withdrawn
-
2016
- 2016-03-01 JP JP2016038729A patent/JP2016104818A/ja not_active Withdrawn
-
2017
- 2017-06-22 US US15/630,592 patent/US10744158B2/en active Active
- 2017-06-22 US US15/630,581 patent/US20170290857A1/en not_active Abandoned
- 2017-11-02 JP JP2017212788A patent/JP6789913B2/ja active Active
-
2020
- 2020-07-14 US US16/928,884 patent/US11833173B2/en active Active
-
2023
- 2023-10-26 US US18/495,532 patent/US20240050480A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | ATP‐responsive smart hydrogel releasing immune adjuvant synchronized with repeated chemotherapy or radiotherapy to boost antitumor immunity | |
| CN104884065B (zh) | 治疗癌症的方法 | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| JP2012504638A5 (https=) | ||
| JP2023085370A5 (https=) | ||
| US20250057851A1 (en) | Therapeutic Modulators of the Reverse Mode of ATP Synthase | |
| JP2011518170A5 (https=) | ||
| SG158919A1 (en) | Constructs binding to phosphatidylserine and their use in disease treatment | |
| AR084816A1 (es) | Metodos y medicamentos para el tratamiento de la enfermedad de alzheimer | |
| JP2014513722A5 (https=) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2011519869A5 (https=) | ||
| Noh et al. | GM-CSF-loaded chitosan hydrogel as an immunoadjuvant enhances antigen-specific immune responses with reduced toxicity | |
| Larsen et al. | Tuberculosis vaccines update: Is an RNA-based vaccine feasible for tuberculosis? | |
| JP2021502392A5 (https=) | ||
| JP2010500284A5 (https=) | ||
| WO2010039924A3 (en) | Th1 vaccination priming for active immunotheraphy | |
| Makedonova et al. | Studying clinical and pathomorphological changes in gingival tissues when applying platelet-rich autoplasma regenerative method | |
| CY1115322T1 (el) | Εκχυλισμα τριγωνελλας για τη θεραπεια νοσων στον ανθρωπο και τα ζωα στις οποιες εμπλεκονται μαστιγομορφα παρασιτα | |
| WO2005084387A3 (en) | Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer | |
| JP2010526884A5 (https=) | ||
| Smit et al. | Enhanced treatment for depression in primary care: first year results on compliance, self-efficacy, the use of antidepressants and contacts with the primary care physician. | |
| St et al. | All you need is light, antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease | |
| Druker | Imatinib (Gleevec®) as a Paradigm of Targeted Cancer Therapies | |
| Ikrar et al. | The Art of Oncoimmunovaccinomics |